Premium
Pretreatment with Albuterol versus Montelukast for Exercise‐Induced Bronchospasm in Children
Author(s) -
Raissy Hengameh H.,
Harkins Michelle,
Kelly Franceska,
Kelly H. William
Publication year - 2008
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.28.3.287
Subject(s) - montelukast , medicine , bronchospasm , asthma , salbutamol , spirometry , crossover study , bronchodilator , metered dose inhaler , anesthesia , inhaler , exercise induced asthma , physical therapy , placebo , alternative medicine , pathology
Study Objectives. To compare pretreatment with albuterol versus montelukast added to the current asthma regimen for protection against exercise‐induced bronchospasm in children with mild‐to‐moderate asthma, and to determine whether cysteinyl leukotriene (Cys‐LT) concentrations measured in the exhaled breath condensate correlated with response to montelukast. Design. Prospective, randomized, double‐blind, double‐dummy, crossover study Setting. Asthma clinic at a university‐affiliated medical center. Patients. Eleven children aged 7–17 years with physician‐diagnosed mild‐to‐moderate asthma for at least 6 months and with self‐reported exercise‐induced bronchospasm (defined as ≤ 15% decrease in forced expiratory volume in 1 sec [FEV 1 ] at screening and baseline visit). Intervention. Patients were randomly assigned to receive 3–7 days of oral montelukast 5–10 mg/day or 2 puffs of an albuterol metered‐dose inhaler just before an exercise challenge and then were crossed over to the alternate therapy for the last visit. Measurements and Main Results. Serial spirometry was performed before and at 0, 5, 10, 15, 30, 45, and 60 minutes after the exercise challenge at each visit. Measurement of exhaled breath condensate was performed at the screening visit and study visits 1 and 2. The primary outcome was the maximum change in FEV 1 after exercise. Secondary outcomes were the area under the curve for FEV 1 (expressed as percentage decrease from baseline) during the first 60 minutes (AUC 0–60 ) after exercise and the proportion of patients in whom exercise‐induced bronchospasm was prevented (defined as < 15% decrease in FEV 1 after exercise challenge). The mean ± SD maximum decrease in FEV 1 was 27.5 ± 7.9% at baseline. Patients receiving montelukast had an 18.3 ± 13.7% decrease in FEV 1 compared with 0.7 ± 1.6% in patients receiving albuterol (p=0.002, paired t test). Exercise‐induced bronchospasm was prevented in 100% of the patients receiving albuterol compared with 55% receiving montelukast (p<0.05, McNemar's test). The AUC 0–60 was significantly smaller with albuterol compared with montelukast (p<0.001, Wilcoxon signed rank test). No correlations were found between Cys‐LT concentration and the severity of exercise‐induced bronchospasm or the response to montelukast. Conclusion. Pretreatment with albuterol is more effective than montelukast for prevention of exercise‐induced bronchospasm in children with asthma.